{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:17:20Z","timestamp":1790007440707,"version":"4.0.1"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene\u2013related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Primary results of the DRAGON study demonstrated the efficacy and safety of erenumab in patients with CM from China and other Asian countries. This post hoc analysis evaluated the rate of reversion from CM to EM in the overall population and in subgroups of patients defined by baseline demographic and clinical characteristics (age, body mass index, gender, prior preventive treatment failure, medication overuse status, and disease duration).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reversion from CM to EM was defined as a reduction in headache frequency to &lt;\u200945 headache days over the 12\u2009weeks of the double\u2010blind treatment period. In addition, migraine\u2010related disability and disease impact on functional impairment were assessed within each treatment group in reverters and non\u2010reverters using the Headache Impact Test\u20106 (HIT\u20106), Migraine Physical Function Impact Diary (MPFID), and modified Migraine Disability Assessment (mMIDAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 557 patients with CM were randomized to monthly erenumab 70 mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009279) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009278), of whom 52.3% (146 of 279) treated with erenumab reverted from CM to EM compared to 41.0% (114 of 278) in the placebo group (odds ratio [OR] 1.59, 95% confidence interval: 1.1\u20132.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Treatment with erenumab resulted in a greater mean change (standard error) from baseline in the HIT\u20106 total score for reverters versus non\u2010reverters compared to placebo (erenumab: \u22129.5 [0.6] vs. \u22125.1 [0.5]; placebo: \u22128.9 [0.7] vs. \u22124.9 [0.5]). A similar pattern was observed for mMIDAS score in erenumab treatment groups versus placebo (erenumab: \u221222.1 [1.2] vs. \u22126.3 [1.8]; placebo: \u221219.9 [1.3] vs. \u22127.9 [1.6]). Substantial improvements were reported in MPFID\u2010Physical Impairment (PI) and Everyday Activities (EA) scores in reverters versus non\u2010reverters in erenumab treatment groups (MPFID\u2010PI: \u22125.9 [0.3] vs. \u22121.9 [0.6]; MPFID\u2010EA: \u22127.9 [0.4] vs. \u22123.4 [0.6]) and in placebo (MPFID\u2010PI: \u22125.4 [0.4] vs. \u22121.0 [0.5]; MPFID\u2010EA: \u22127.1 [0.5] vs. \u22123.2 [0.5]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis demonstrated that a greater proportion of patients treated with erenumab reverted from CM to EM compared to patients treated with placebo. The reversion from CM to EM was reflected by the greater improvements in patient\u2010reported outcomes in the erenumab group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14733","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T08:19:32Z","timestamp":1716538772000},"page":"143-152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the\n                    <scp>DRAGON<\/scp>\n                    study"],"prefix":"10.1111","volume":"65","author":[{"given":"Shuu\u2010Jiun","family":"Wang","sequence":"first","affiliation":[{"name":"Neurological Institute Taipei Veterans General Hospital  Taipei Taiwan"},{"name":"Brain Research Center and College of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung\u2010Kun","family":"Kim","sequence":"additional","affiliation":[{"name":"Nowon Eulji Medical Center Eulji University School of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebo","family":"Wang","sequence":"additional","affiliation":[{"name":"Hebei General Hospital  Shijiazhuang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiying","family":"Zhou","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wan","sequence":"additional","affiliation":[{"name":"Jiangsu Province Hospital  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingmin","family":"Yu","sequence":"additional","affiliation":[{"name":"The Second Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Lian","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Arkuszewski","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Ecochard","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Snellman","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Wen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yin","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for Biomedical Research Co, Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for Biomedical Research Co, Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Su","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"e_1_2_14_2_1","volume-title":"Harrison's Principles of Internal Medicine, 20e","author":"Goadsby PJ","year":"2018"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002275"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420919098"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01941.x"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d8af2"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01111-8"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1066-0"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14056"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_14_20_1","first-page":"721","article-title":"Guide to the prevention and treatment of migraine in China [Chinese]","volume":"22","author":"Chinese Medical Association Group","year":"2016","journal-title":"Chin J Pain Med"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1729-3"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01117-2"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211024160"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01514-9"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14138"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420973994"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01171-w"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13997"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13549"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11226-4"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000113747.18760.d2"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181974b19"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14194"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05426"},{"key":"e_1_2_14_38_1","first-page":"344","article-title":"Evaluating clinically meaningful within\u2010subject change in functioning associated with migraine prevention using the Migraine Physical Function Impact Diary (MPFID)","volume":"37","author":"Kawata AK","year":"2017","journal-title":"Cephalalgia"},{"issue":"7","key":"e_1_2_14_39_1","first-page":"735","article-title":"Placebo effects in treating migraine and other headaches","volume":"11","author":"Diener HC","year":"2010","journal-title":"Curr Opin Investig Drugs"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:41:28Z","timestamp":1762083688000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/head.14733"],"URL":"https:\/\/doi.org\/10.1111\/head.14733","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"2023-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}